RxDoctor Payments Data

Lance Siegel, MD

Gastroenterology · Goshen, NYNPI 1184622672

Payments from drug & device makers

$17,269in general payments, 2019–2025

Across 850 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • QOL Medical, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Sanofi$773
  • plus $6K from 32 others

What the payments were for

  • Speaking & faculty fees$4002%
  • Food & beverage$16,86198%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,269 in reported general payments places this provider in the 80th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$493,762
Medicare patients
1,230
Services billed
3,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab26$644,384
CreonLipase/Protease/Amylase132$357,082
ZenpepLipase/Protease/Amylase102$333,051
XifaxanRifaximin38$164,400
LinzessLinaclotide69$86,783
Mesalamine55$52,547
PentasaMesalamine18$50,891
Dexlansoprazole DrDexlansoprazole61$34,248
PertzyeLipase/Protease/Amylase11$28,034
Mesalamine ErMesalamine46$15,899
TrulancePlecanatide25$15,671
Pantoprazole Sodium639$10,565
Famotidine372$8,431
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates132$8,394
Sucralfate48$8,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$2,440$644,38426 claims
AbbVieCreon, Linzess$4,125$443,865201 claims
Aimmune Therapeutics, Inc.Zenpep$260$333,051102 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,761$180,07163 claims
Redhill Biopharma Inc.Movantik$200$4,95512 claims
Ferring Pharmaceuticals Inc.Clenpiq$201$4,77028 claims
Braintree Laboratories, Inc.Sutab$148$3,95725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Goshen

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →